Product Description
Omalizumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that binds with a higher affinity to free IgE and inhibits the binding of free IgE to high-affinity IgE receptor (Fc?RI) expressed on mast cells and basophils. This results in the downregulation of Fc?RI and decreased release of mediators of inflammatory response. Omalizumab neither binds directly to the high-affinity IgE receptor (Fc?RI) nor the receptor-bound IgE. This monoclonal antibody was developed by Tanox, Novartis, and Genentech and received approval from the FDA in 2009 for the treatment of allergic asthma. Recently, it has been approved for the treatment of chronic spontaneous urticaria (CIU).
Biovision | A2145 | Anti-IgE (Omalizumab), Humanized Antibody DataSheet
Antibody Target: Human Immunoglobulin E (IgE)
Target Alternative Name: IGE25, Olizumab, pSVIE26, rhuMab-E25, IGHE
Tag Line: Omalizumab is a recombinant DNA-derived humanized monoclonal antibody that selectively targets free human IgE and prevents its association with the receptor Fc?RI, thereby reducing sensitivity to allergens. This monoclonal antibody received FDA approval to treat allergic asthma
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Omalizumab
Accession #: DB00043 (BTD00081, BIOD00081)
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application: In vitro studies
Positive Control:
Application And Usages: In vitro studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE